152 related articles for article (PubMed ID: 30985721)
1. Benzbromarone as a possible cause of acute kidney injury in patients with urolithiasis: Two case reports.
Ye X; Wu J; Tang K; Li W; Xiong C; Zhuo L
Medicine (Baltimore); 2019 Apr; 98(15):e15214. PubMed ID: 30985721
[TBL] [Abstract][Full Text] [Related]
2. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
Perez-Ruiz F; Hernandez-Baldizon S; Herrero-Beites AM; Gonzalez-Gay MA
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1299-305. PubMed ID: 20506124
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
Yu H; Liu X; Song Y; Cheng J; Bao H; Qin L; Zhou X; Wang L; Peng A
Clin Exp Nephrol; 2018 Dec; 22(6):1324-1330. PubMed ID: 29761242
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease.
Fujimori S; Ooyama K; Ooyama H; Moromizato H
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1035-8. PubMed ID: 22132953
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia.
Gao H
Pak J Pharm Sci; 2019 Jul; 32(4(Supplementary)):1869-1871. PubMed ID: 31680085
[TBL] [Abstract][Full Text] [Related]
6. Hyperuricemia and Acute Renal Failure in Renal Transplant Recipients Treated With High-Dose Mizoribine.
Akioka K; Ishikawa T; Osaka M; Kadotani Y; Okugawa K; Nakano K; Osaka Y; Tsuchiya K; Sako H
Transplant Proc; 2017; 49(1):73-77. PubMed ID: 28104163
[TBL] [Abstract][Full Text] [Related]
7. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
[TBL] [Abstract][Full Text] [Related]
8. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?
Lee MH; Graham GG; Williams KM; Day RO
Drug Saf; 2008; 31(8):643-65. PubMed ID: 18636784
[TBL] [Abstract][Full Text] [Related]
9. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
10. [Uricosuric agent].
Ohno I
Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
Nakata T; Ikeda S; Koga S; Yonekura T; Tsuneto A; Doi Y; Fukae S; Minami T; Kawano H; Maemura K
Int Heart J; 2020 Sep; 61(5):984-992. PubMed ID: 32921665
[TBL] [Abstract][Full Text] [Related]
12. Fulminant hepatic failure associated with benzbromarone treatment: a case report.
Arai M; Yokosuka O; Fujiwara K; Kojima H; Kanda T; Hirasawa H; Saisho H
J Gastroenterol Hepatol; 2002 May; 17(5):625-6. PubMed ID: 12084041
[No Abstract] [Full Text] [Related]
13. Letter by George regarding article, "Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled cross-over preliminary study".
George J
Circ Heart Fail; 2010 May; 3(3):e10; author reply e14. PubMed ID: 20484184
[No Abstract] [Full Text] [Related]
14. Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients.
Kurajoh M; Koyama H; Shoji T; Sumida C; Yamamoto A; Tsutsumi Z; Moriwaki Y; Yamamoto T; Koga M
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):265-71. PubMed ID: 22456297
[TBL] [Abstract][Full Text] [Related]
15. Stopping progression in familial juvenile hyperuricemic nephropathy with benzbromarone?
Lhotta K
Kidney Int; 2003 Nov; 64(5):1920-1. PubMed ID: 14531831
[No Abstract] [Full Text] [Related]
16. Fatal fulminant hepatic failure associated with benzbromarone.
Wagayama H; Shiraki K; Sugimoto K; Fujikawa K; Shimizu A; Takase K; Nakano T; Tameda Y
J Hepatol; 2000 May; 32(5):874. PubMed ID: 10845680
[No Abstract] [Full Text] [Related]
17. Is hyperuricemia a risk factor for arteriosclerosis? Uric acid and arteriosclerosis in apolipoprotein e-deficient mice.
Wakuda H; Uchida S; Ikeda M; Tabuchi M; Akahoshi Y; Shinozuka K; Yamada S
Biol Pharm Bull; 2014; 37(12):1866-71. PubMed ID: 25451835
[TBL] [Abstract][Full Text] [Related]
18. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
Reinders MK; van Roon EN; Houtman PM; Brouwers JR; Jansen TL
Clin Rheumatol; 2007 Sep; 26(9):1459-65. PubMed ID: 17308859
[TBL] [Abstract][Full Text] [Related]
19. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
[TBL] [Abstract][Full Text] [Related]
20. Acute renal failure caused by hyperuremic acidemia in ABO-incompatible kidney transplant maintained with cyclosporine and high-dose mizoribine: a case report.
Akioka K; Masuda K; Harada S; Nakamura T; Okugawa K; Nakano K; Osaka Y; Tsuchiya K; Sako H
Transplant Proc; 2013 Sep; 45(7):2815-8. PubMed ID: 24034056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
